Enterprise Value

10.2M

Cash

36.57M

Avg Qtr Burn

-9.404M

Short % of Float

1.40%

Insider Ownership

0.31%

Institutional Own.

17.76%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CRB-701 (Nectin-4 ADC) Details
Solid tumor/s, Urothelial cancer

Phase 1

Initiation

IND

Submission

Lenabasum Details
Genetic disorder, Chronic inflammatory disorder, Rare genetic disease, Inflammatory disease

Failed

Discontinued

Lenabasum Details
Cystic fibrosis

Failed

Discontinued

Lenabasum Details
Systemic sclerosis

Failed

Discontinued

Failed

Discontinued